Key Development
Consumer goods giant Procter & Gamble Co. (NYSE: PG) has entered into a definitive agreement to acquire premium wellness and supplement brand Thorne HealthTech from private equity firm L Catterton for an enterprise valuation of $3.8 billion.
The transaction was publicly confirmed by P&G CEO Shailesh Jejurikar on CNBC’s “Squawk on the Street” on August 4, 2026. Subject to customary regulatory approvals and closing conditions, the deal is slated for completion in the second half of 2026.
Transaction Structure & Financial Milestones:
-
Selling Entity: L Catterton’s Flagship Fund (the private equity firm backed by luxury group LVMH).
-
Deal Valuation: $3.8 billion. The sale marks a substantial return exceeding $3 billion for L Catterton, which previously took Thorne private in 2023 for $680 million.
-
Thorne Revenue Footprint: Thorne’s annual top-line revenue surpassed $500 million in 2025, driven by rapid direct-to-consumer (D2C) channel expansion.
Why It Matters
-
Expanding P&G’s Personal Health Care Ecosystem: Thorne joins P&G’s existing digestive health and wellness portfolio, which includes Metamucil (fiber), Align Probiotic, New Chapter (organic vitamins), alongside legacy consumer health brands Vicks and Oral-B.
-
Capturing Gen Z & Millennial Demographics: Consumers under 40 account for the largest share of Thorne’s customer base. The brand maintains a strong market posture in science-backed, personalized nutrition, supported by partnerships with professional sports teams and clinical testing platforms.
-
Consolidation Across the Vitamin, Mineral, and Supplement (VMS) Sector: P&G’s $3.8 billion acquisition reflects broader M&A momentum across the VMS category: competitor Unilever recently acquired U.S. gummy supplement maker Grüns, while Nestlé initiated a strategic review of its slower-growing supplement lines. Consumer health firm Haleon had also evaluated Thorne prior to P&G securing the deal.
Healthcare Insight Analysis
From the perspective of Healthcare Insight, P&G’s $3.8 billion acquisition of Thorne represents The Pharmaceuticalization of Wellness.
As mature Fast-Moving Consumer Goods (FMCG) categories encounter margin compression, global consumer health majors are pivoting toward high-margin, high-growth wellness subsectors characterized by strong brand stickiness and recurring customer lifetime value. Thorne fulfills both strategic criteria:
-
Science-Backed Credibility: Unlike mass-market retail vitamins, Thorne built its commercial reputation on stringent testing protocols, medical professional endorsements, and clinical formulation standards. Formulated without unnecessary fillers and backed by NSF Certified for Sport® accreditations, the brand commands high consumer trust.
-
D2C Infrastructure & Personalized Subscriptions: Thorne leverages proprietary biological testing kits (e.g., blood and microbiome panels) to deliver personalized nutrient regimens. This data-driven model sustains high recurring subscription rates, generating predictable cash flows for P&G.
Paul Gama, CEO of P&G Health Care, emphasized that the acquisition positions P&G to capitalize on growing consumer demand for preventive care, self-care, and personalized health solutions.
Market Implications
-
Positive Share Price Reaction: Procter & Gamble equity traded up ~1% following the announcement, reflecting positive institutional sentiment toward adding a high-margin growth asset.
-
Accelerating Thorne’s Global Market Footprint: Leveraging P&G’s global supply chain and international retail distribution network spanning over 180 countries will allow Thorne to expand beyond North America into Asian and European markets.
-
Establishing M&A Valuation Benchmarks in Wellness: Paying $3.8 billion for a $500 million revenue asset establishes a new M&A valuation multiple (~7.6x revenue) for premium, R&D-backed supplement platforms.
Transaction Summary: P&G Acquisition of Thorne HealthTech
| Deal Parameter | Financial & Regulatory Specifications | Strategic Significance |
| Acquiring Entity | Procter & Gamble (P&G) (NYSE: PG) | Expands Personal Health Care portfolio into premium wellness. |
| Selling Sponsor | L Catterton (Flagship Fund) | Generates > $3 billion net gain over 2023 take-private cost basis. |
| Enterprise Value | $3.8 Billion | Represents the largest VMS transaction year-to-date in 2026. |
| Thorne Revenue (2025) | > $500 Million | Driven by direct-to-consumer (D2C) growth and under-40 demographics. |
| Complementary Brands | Metamucil, Align Probiotic, New Chapter | Builds an integrated digestive, probiotic, and vitamin platform. |
Source: https://qz.com/procter-gamble-acquiring-thorne-supplements-3-8-billion-080426